Under the agreements, Bioké, a business unit of Cell Signaling Technology Europe, will distribute the two platforms in the Netherlands, Belgium, and Luxembourg.
Using single-cell and bulk RNA sequence data, investigators identified four pathway-based GBM subtypes, including a mitochondrial subtype that appears to respond to related inhibitors.
